Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-04-01
2008-04-01
Whiteman, Brian (Department: 1635)
Chemistry: molecular biology and microbiology
Vector, per se
Reexamination Certificate
active
07351577
ABSTRACT:
One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second nucleotide sequences collectively encode a functional Factor VIII protein. Another form of the composition is a recombinant adeno-associated virus containing a nucleotide sequence encoding functional Factor VIII light or heavy chain operably linked to a tissue-specific promoter.
REFERENCES:
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4886876 (1989-12-01), Zimmerman et al.
patent: 4965199 (1990-10-01), Capon et al.
patent: 5004803 (1991-04-01), Kaufman et al.
patent: 5045455 (1991-09-01), Kuo et al.
patent: 5112950 (1992-05-01), Meulien et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5149637 (1992-09-01), Scandella et al.
patent: 5171844 (1992-12-01), Van Ooyen et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5252479 (1993-10-01), Zrivastava
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5422260 (1995-06-01), Kaufman et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5451521 (1995-09-01), Kaufman et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5563045 (1996-10-01), Pitman et al.
patent: 5580703 (1996-12-01), Kotin et al.
patent: 5587308 (1996-12-01), Carter et al.
patent: 5587310 (1996-12-01), Kane et al.
patent: 5595886 (1997-01-01), Chapman et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5633150 (1997-05-01), Wood et al.
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5658785 (1997-08-01), Johnson
patent: 5661008 (1997-08-01), Almstedt et al.
patent: 5668108 (1997-09-01), Capon et al.
patent: 5677158 (1997-10-01), Zhou et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5693499 (1997-12-01), Yonemura et al.
patent: 5693531 (1997-12-01), Chiorini et al.
patent: 5720720 (1998-02-01), Laske et al.
patent: 5789203 (1998-08-01), Chapman et al.
patent: 5843742 (1998-12-01), Natsoulis et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5861314 (1999-01-01), Philip et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 6221646 (2001-04-01), Dwarki et al.
patent: 6268212 (2001-07-01), Simonet
patent: 2002/0155580 (2002-10-01), Snyder et al.
patent: 0 182 448 (1986-05-01), None
patent: 0 220 618 (1986-10-01), None
patent: O 160 457 (1991-01-01), None
patent: 0 162 067 (1992-07-01), None
patent: 0 232 112 (1993-12-01), None
patent: 0 592 836 (1994-04-01), None
patent: 0 670 332 (1995-09-01), None
patent: 0 672 138 (1995-09-01), None
patent: 0 786 474 (1997-07-01), None
patent: 0 795 021 (1997-09-01), None
patent: 0 500 734 (1998-02-01), None
patent: 0 506 757 (1998-08-01), None
patent: 0 847 057 (1998-10-01), None
patent: 0 533 862 (1999-10-01), None
patent: WO 87/07144 (1987-12-01), None
patent: WO 88/09809 (1988-12-01), None
patent: WO 89/03429 (1989-04-01), None
patent: WO 91/07490 (1991-05-01), None
patent: WO 91/09122 (1991-06-01), None
patent: WO 92/01070 (1992-01-01), None
patent: WO 92/03545 (1992-03-01), None
patent: WO 92/08981 (1992-05-01), None
patent: WO 92/16557 (1992-10-01), None
patent: WO 93/03367 (1993-02-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 04/11503 (1994-05-01), None
patent: WO 94/13788 (1994-06-01), None
patent: WO 95/07995 (1995-03-01), None
patent: WO 96/13698 (1996-05-01), None
patent: WO 96/15777 (1996-05-01), None
patent: WO 96/21035 (1996-07-01), None
patent: WO 97/03195 (1997-01-01), None
Aiello et al,, Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo kidney Cells (KEY-Ad-5 or 293)Virol, 94:460-469 (1979).
Antonarakis et al, “Molecular Genetics of Hemophilia A in Man (Factor VIII Deficiency),”Mol Boil. Med., 4:81-94 (1987).
Berns, “Parvoviridae and Their Replication,” in Fields and Knipes (eds.),Fundamental Virology, 2ndEd., pp. 817-837 (1991).
Boshart et al., “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,”Cell41:521-530 (1985).
Buller et al, “Herpes Simplex Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication,”J. Virol., 40:241-247 (1981).
Capecchi, “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells,”Cell22:479-488 (1980).
Carter, “Adeno-Associated Virus Helper Functions,” inCRC Handbook of Parvovirusesvol. I (P. Tijssen, ed.), pp. 533-539 (1990).
Carter, “Adeno-associated virus vectors,”Curr, Opin. Biol., 3:533-539 (1992).
Chu et al, “SV40 DNA transfection of cells in suspension; analysis of the efficiency of transcription and translation of T-antigen,”Gene 13:197-202 (1981).
Costa and Grayson, “Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promotor reveal synergistic interactions with its enhancer region,”Nucl. Acids, Res., 19:4139-4145 (1991).
Costa et al., “Transcriptional Control of the Mouse Prealbumin (Transthyretin) Gene: Both Promoter Sequences and a Distinct Enhancer Are Cell Specific,”Mol. Cell. Biol., 6:4697 (1986).
Davis et al.,Basic Methods in Molecular Biology, Elsevier (1986) (Title and Copyright Pages Only).
Dijkema et al. “Closing and Expression of the chromosomal immune interferon gene of the rat,”EMBO J.4:761-767 (1985).
Edge, “Total Synthesis of a Human Leukocyte Interferon Gene,”Nature292:756-761 (1981).
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc Natl. Acad. Sci U.S.A.84: 7413-7417 (1987).
Ganz et al, “Human factor VIII from hepatinized plasma; purification and characterization of a single-chain form,”Eur. J. Biochem., 170:521-528 (1988).
Glover et al. (ed.)DNA Cloning: A Practical Appraoch, vols. I and II, Oxford; New York: IRL Press (1995) (Title and Copyright Pages Only).
Gorman et al., “The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection,”Prod. Natl. Acad. Sci USA79: 6777-6781 (1982).
Graham and Van der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virol., 52: 456-467 (1973).
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,”J. Gen. Virol., 36:59-72 (1977).
Herzog, et al., “Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IV mediated by adeno-associated viral vector,”Nature Med., 5:56-63 (1999).
Janik et al., “Locations of adenovirus genes required for the relpication of adenovirus-associated virus,”Proc. Natl. Acad. Sci. USA78:1925-1929 (1981).
Jay et al., “Chemical Synthesis of a Biologically Active Gene for Human Immune Interferon-γ,”J Biol. Chem.259:6311-6317 (1984).
Kaufman eta l., “Synthesis, Processing and Secretion of Recombinant Human Factor VII Expressed in Mammalian Cells,”J. Biol. Chem., 263:6352-6362 (1988).
Kaufman, “Biological Regulation of Factor VIII Activity,”Ann. Rev. Med., 43:325-339 (1992).
Kim et al., “Use of the human elongation factor 1α promoter as a versatile and efficient expression system,”Gene91:217-223 (1990).
Klein et al., “High-velocity microprojectives for delivering nucleic acids into living cells,”Nature327:70-73 (1987).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Hum. Gen. Ther., 5:793-801 (1994).
Lebkowski et al., “Adeno-Associated Virus: a Vector System for Effi
Colosi Peter C.
Couto Linda B.
Qian Xiaobing
Genzyme Corporation
Whiteman Brian
LandOfFree
Adeno-associated vector compositions for expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adeno-associated vector compositions for expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adeno-associated vector compositions for expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768316